Fundz
Back to SEC Filings
10-QHIGH RiskDETERIORATING

VITASPRING BIOMEDICAL CO. LTD.

Filed: Apr 22, 2026 CIK: 0001697884
View original filing on SEC.gov

AI Executive Summary

AI-powered analysis of 10-Q filing content

VitaSpring Biomedical shows severe financial distress with zero revenues, mounting losses, and critical liquidity issues. The company has only $5,525 in cash against $3.8M in current liabilities, creating an immediate going concern. Stockholders' deficit has expanded to $3.7M, indicating potential insolvency.

Red Flags Detected (6)

Zero revenues for all reported periods - no business operations generating income

Critical liquidity crisis: $5,525 cash vs $3.8M current liabilities (99.9% shortfall)

Stockholders' deficit of $3.7M indicates technical insolvency

3 more red flags detected

Key Takeaways

Company appears to be in pre-revenue biomedical development stage with no commercial products

Current burn rate of ~$218K per quarter with zero revenue is unsustainable

2 more takeaways

Filing Overview

Form TypeQuarterly Report (10-Q)
Filing DateApr 22, 2026
Risk LevelHIGH
TrendDETERIORATING
AI Confidence85%
Red Flags6

What This Means

High Risk Filing: This company is showing signs of financial stress or significant operational challenges.

Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.

Quarterly Report: Interim filing with unaudited financial data for the quarter.

View Full Filing on SEC.govBrowse More Filings